Circulating cell-free RNA signatures for the characterization and diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome
- PMID: 40789036
- PMCID: PMC12377778
- DOI: 10.1073/pnas.2507345122
Circulating cell-free RNA signatures for the characterization and diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome
Abstract
People living with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) experience heterogeneous and debilitating symptoms that lack sufficient biological explanation, compounded by the absence of accurate, noninvasive diagnostic tools. To address these challenges, we explored circulating cell-free RNA (cfRNA) as a blood-borne bioanalyte to monitor ME/CFS. cfRNA is released into the bloodstream during cellular turnover and reflects dynamic changes in gene expression, cellular signaling, and tissue-specific processes. We profiled cfRNA in plasma by RNA sequencing for 93 ME/CFS cases and 75 healthy sedentary controls, then applied machine learning to develop diagnostic models and advance our understanding of ME/CFS pathobiology. A generalized linear model with least absolute shrinkage selector operator regression trained on condition-specific signatures achieved a test-set AUC of 0.81 and an accuracy of 77%. Immune cfRNA deconvolution revealed differences in platelet-derived cfRNA between cases and controls, as well as elevated levels of plasmacytoid dendritic, monocyte, and T cell-derived cfRNA in ME/CFS. Biological network analysis further implicated immune dysfunction in ME/CFS, with signatures of cytokine signaling and T cell exhaustion. These findings demonstrate the utility of RNA liquid biopsy as a minimally invasive tool for unraveling the complex biology behind chronic illnesses.
Keywords: ME/CFS; cell signaling; cell-free RNA; diagnosis; machine learning.
Conflict of interest statement
Competing interests statement:I.D.V. is a member of the Scientific Advisory Board of Karius Inc., Kanvas Biosciences and GenDX, and receives consulting fees from Eurofins Viracor. I.D.V. is listed as an inventor on submitted patents pertaining to cell-free nucleic acids (US patent applications 63/237,367, 63/429,733, 63/056,249, 63/015,095, 16/500,929, 41614P-10551-01-US). M.R.H. is on the Scientific Advisory Boards of the Open Medicine Foundation, Simarron Research, and Solve ME/CFS initiative, which support research on ME/CFS.
References
-
- CDC, Clinical overview of ME/CFS. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (2024). https://www.cdc.gov/me-cfs/hcp/clinical-overview/index.html. Accessed 16 July 2024.
-
- Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine, Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness (National Academies Press (US), 2015). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
